Regulatory Ray Therapeutics receives EMA PRIME status for gene therapy Pharmaceutical TechnologyRay Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).Gene Therapy PlatformRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaceutical Technology Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP). Gene Therapy Platform Read full story Post navigation Previous: Survodutide delivers 16.6% weight loss in major phase 3 obesity trialNext: Regeneron Q1 2026 net income falls 10% to $727m Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026